To undertake a selective review of the epidemiology, etiology, and treatment of tardive dyskinesia (TD), with emphasis on the potential influence of estrogen in its expression.
Method:
Both Medline and Psycinfo databases were used to search for articles with the following key words: tardive dyskinesia, humans, animals, dopamine, estrogen, estrogen replacement therapy, antioxidants and oxidative stress.
Results:
The studies reviewed here suggest that estrogen modulates dopamine-mediated behaviours and that it protects against oxidative stress-induced cell damage caused by long-term exposure to antipsychotic medication.
Conclusions:
Estrogen's multimodal role in the central nervous system may prove useful for the amelioration or prevention of TD. All the evidence suggests that a placebo-controlled, randomized trial with safer forms of estrogen should be conducted in postmenopausal women with TD.
SaltzBLKaneJMWoernerMGLiebermanJAAlvirJJ. Aging and tardive dyskinesia. In: YassaRNairNPVJesteDV, editors. Neuroleptic-induced movement disorders. New York: Cambridge University Press; 1997. p 13–25.
2.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders: Fourth ed. Washington (DC): American Psychiatric Press; 1994.
3.
CaseyDE. Neuroleptic-induced extrapyramidal syndromes and tardive dyskinesia. In: HirschSWeinbergerDR, editors. Schizophrenia. Oxford (UK): Blackwell; 1995. p 546–65.
4.
AllikmetsLHZarkovskyAMNurckAM. Changes in catalepsy and receptor sensitivity following chronic neuroleptic treatment. Eur J Pharmacol1981;75:145–7.
5.
FriedmanEGianutosGKusterJ. Chronic fluphenazine and clozapine elicit opposite changes in brain muscarinic receptor binding: Implications for understanding tardive dyskinesia. J Pharmacol Exp Ther1983;226:7–12.
6.
SilvestriSSeemanMVNegreteJCHouleSShammiCM, Remington GJ, and others. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: A clinical PET study. (Submitted for publication.).
7.
SmithJMKucharskiLTOswaldWTWatermanLJ. Tardive dyskinesia: Effect of age, sex, and criterion level of symptomatology on prevalence estimates. Psychopharmacol Bull1979;15:69–71.
YassaRJesteDV. Gender differences in tardive dyskinesia: A critical review of the literature. Schizophr Bull1992;18:701–15.
10.
van OsJFahyTJonesPHarveyITooneBMurrayR. Tardive dyskinesia: Who is at risk?Acta Psychiatr Scand1997;96:206–16.
11.
KanisJAMeltonLJChristiansenCJohnstonCCKhaltaevN. The diagnosis of osteoporosis. J Bone Miner Res1994;9:1137–41.
12.
GordonJHDiamondBl. Antagonism of dopamine supersensitivity by estrogen: Neurochemical studies in an animal model of tardive dyskinesia. Biol Psychiatry1981;16:365–71.
13.
WaddingtonJL. Schizophrenia, affective psychoses, and other disorders treated with neuroleptic drugs: The enigma of tardive dyskinesia, its neurobiological determinants, and the conflict of paradigms. Int Rev Neurobiol1989;31:297–353.
14.
SeemanPChau-WongMTedescoJWongK. Brain receptors for antipsychotic drugs and dopamine: Direct binding assays. Proc Natl Acad Sci USA1975;72:4376–80.
15.
ClowATheodorouAJennerPMarsdenCD. Changes in rat striatal dopamine turnover and receptor activity during years of neuroleptic administration. Eur J Pharmacol1980;63:135–44.
16.
HafnerHBehrensSDe VryJGattazWF. An animal model for the effects of estradiol on dopamine-mediated behaviour: Implications for sex differences in schizophrenia. Psychiatry Res1991;38:125–34.
17.
PerryKODiamondBIFieldsJZGordonJH. Hypophysectomy induced hypersensitivity to dopamine: Antagonism by estrogen. Brain Res1981;226:211–9.
18.
FieldsJZGordonJH. Estrogen inhibits the dopaminergic supersensitivity induced by neuroleptics. Life Sci1982;30:229–34.
19.
MisraCHShelatHSmithRC. Age affects dopamine receptor changes during chronic administration of fluphenazine. Eur J Pharmacol1982;85:343–6.
20.
RandallPKSeversonJAFinchCE. Aging and the regulation of striatal dopaminergic mechanisms in mice. J Pharmacol Exp Ther1981;219:695–700.
21.
BlinJBaronJCCambonHBonnetAMDuboisB, Loc'h C and others. Striatal dopamine D2 receptors in tardive dyskinesia: A PET study. J Neurol Neurosurg Psychiatry1989;52:1248–52.
22.
AnderssonUEckemasS-AHartvigPUlinJLangstromBHaggstromJ-E. Striatal binding of 11C-NMSP studied with positron emission tomography in patients with persistent tardive dyskinesia: No evidence for altered dopamine D2 receptor binding. J Neural Transm Gen Sect1990;79:215–26.
23.
KlawansHLRubovitsR. An experimental model of tardive dyskinesia. J Neural Transm1972;33:235–46.
24.
CadetJLLohrJBJesteDV. Free radicals and tardive dyskinesia. Trends Neurosci1986;9:107–8.
25.
HalliwellBGutteridgeJMC. Free Radicals in Biology and Medicine. Oxford (UK): Clarendon Press; 1993.
26.
StauntonDAMagistrettiPJKoobGFShoemakerWJBloomFE. Dopaminergic supersensitivity induced by denervation and chronic receptor blockade is additive. Nature1982;299:72–4.
27.
SagaraY. Induction of reactive oxygen species in neurons by haloperidol. J Neurochem1998;71:1002–12.
28.
GoodmanYBruceAJChengBMattsonMP. Estrogens attenuate and corticoster-one exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons, J Neurochem1996;66:1836–44.
29.
GordonJHBorisonRLDiamondBI. Modulation of dopamine receptor sensitivity by estrogen. Biol Psychiatry1980;15:389–96.
30.
TonnaerJALeindersTvan DelftAM. Ovariectomy and subchronic estradiol-17 beta administration decrease dopamine D1 and D2 receptors in rat striatum. Psychoneuroendocrinology1989;14:469–76.
31.
CloptonJKGordonJH. The possible role of 2-hydroxyestradiol in the development of estrogen-induced striatal dopamine receptor hypersensitivity. Brain Res1985;333:1–10.
32.
Van HartesveldtCJoyceJN. Effects of estrogen on the basal ganglia. Neurosci Biobehav Rev1986;10:1–14.
33.
Fernandez-RuizJJAmorJCRamosJA. Time-dependent effects of estradiol and progesterone on the number of striatal dopaminergic D2-receptors. Brain Res1989;476:388–95.
34.
VilleneuveACazejustTCoteM. Estrogens in tardive dyskinesia in male psychiatric patients. Neuropsychobiology1980;6:145–51.
35.
GlazerWMNaftolinFMorgensternHBameaERMacLuskyNJBrennerLM. Estrogen replacement and tardive dyskinesia. Psychoneuroendocrinology1985;10:345–50.
36.
GlazerWMNaftolinFMooreDCBowersMBMacLuskyNJ. The relationship of circulating estradiol to tardive dyskinesia in men and postmenopausal women. Psychoneuroendocrinology1983;8:429–34.
37.
GlazerWMMooreDCBowersMBBrownWA. Serum prolactin and tardive dyskinesia. Am J Psychiatry1981;138:1493–6.
38.
KollerWCBarrABiaryN. Estrogen treatment of dyskinetic disorders. Neurology1982;32:547–9.
39.
Saunders-PullmanRGordon-ElliottJParidesMFahnSSaundersHRBressmanS. The effect of estrogen replacement on early Parkinson's disease. Neurology1999;52:1417–21.
40.
Canadian Pharmaceutical Association. Compendium of pharmaceuticals and specialties: thirtieth edition. Ottawa: The Association; 1995.
41.
BryantHUDereWH. Selective estrogen receptor modulators: An alternative to hormone replacement therapy. Proc Sci Exp Bio Med1998;217:45–52.
GenazzaniARSpinettiAGalloRBernardiF. Menopause and the central nervous system: Intervention options. Maturitas1999;31:103–10.
44.
BeasleyCMDellvaMATamuraRNMorgensternHGlazerWM, Ferguson K and others. Randomized double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. Br J Psychiatry1999;175:23–30.
